Latest Administration News

CVC Limited has addressed ASX concerns over a delayed Appendix 3Y filing related to director John Leaver’s interest change, attributing the delay to administrative oversight while affirming existing compliance policies.

Dome Gold Mines Ltd launches a $3 million convertible note offering to fund key developments in Fiji, including the Sigatoka Feasibility Study and expanded exploration for copper, gold, and silver.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

Haranga Resources is set to launch a 4,000-metre reverse circulation drilling program at its Ibel South Gold Project in Senegal, aiming to extend high-grade gold mineralisation at depth and explore fresh anomalies identified by termite mound sampling.

Andromeda Metals faces uncertainty in securing cornerstone funding for its Great White Project due to Middle East geopolitical tensions, while pushing forward with its High Purity Alumina pilot plant commissioning.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Macarthur Minerals has successfully raised A$1.25 million through an oversubscribed placement, positioning the company to advance exploration and maintain tenements at its Lake Giles Iron Project.

Cleo Diagnostics has completed blood sample collection for its pivotal U.S. clinical trial, advancing its Pre-Surgical Ovarian Cancer Test closer to FDA submission.

Nexsen Limited's subsidiary has won a HK$6 million grant to accelerate clinical validation and manufacturing of its rapid Group B Streptococcus diagnostic in Hong Kong, positioning the city as a key Asia-Pacific hub.

Temas Resources Corp has opted to reduce its financial reporting frequency, moving from quarterly to semi-annual reports under a Canadian Securities Exchange pilot program. This change aligns with its status as a venture issuer and reflects its ongoing focus on proprietary processing technology and mineral projects.

Genetic Technologies Limited remains under voluntary administration with minimal cash outflows and $0.276 million in cash as it navigates its Deed of Company Arrangement.